Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

By Manas Mishra (Reuters) - Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry. Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States.

Reuters February 22, 2019 02:05:31 IST
Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals defends 375000 drug price after Bernie Sanders rebuke

By Manas Mishra

(Reuters) - Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States.

Drug pricing has been a major talking point in the US for the past few years. It was also one of the campaign promises made by President Donald Trump in the 2016 elections. However, healthcare costs have not gone down significantly.

Last month, the Trump administration proposed a rule to overhaul the industry's system of rebates, or discounts, while Sanders unveiled legislation aimed at lowering drug prices.

For years, patients were able to get Firdapse for free from Jacobus Pharmaceuticals, a small New Jersey-based drug company that offered the drug through a U.S. Food and Drug Administration (FDA) program called Compassionate Use.

The program allows patients with rare diseases and conditions access to drugs not yet approved outside of a clinical trial, when there is no viable alternative.

Catalyst bought the U.S. rights to the drug in 2012 and got approval to sell it in the US in November last year.

Sanders said in a statement provided to Reuters on Thursday that Catalyst had shown a "blatant disregard for patients with LEMS (Lambert-Eaton Myasthenic Syndrome)" who he said were already rationing their medication because of the high price-tag.

"I will ask FDA Commissioner Gottlieb to act immediately to help patients who are suffering," said Sanders, who is seeking the Democratic Party's presidential nomination in 2020.

The company said, before its November approval, only about 200 of an estimated 3,000 LEMS patients in the US received some form of Firdapse, pointing to a large unmet medical need.

"Now, for the first time, LEMS patients have confidence their therapy is FDA approved and is safe and effective," Catalyst's Chief Executive Officer Patrick McEnany said in a letter (https://bit.ly/2NkmIRU).

The company said that Firdapse's price was similar to other medicines that provide a significant clinical benefit in treating ultra-rare diseases, adding it believed the drug would be widely reimbursed by insurers for the small population it treats.

(Reporting by Manas Mishra and Aakash Jagadeesh Babu in Bengaluru and Yasmeen Abutaleb in Washington; Editing by Arun Koyyur and Sweta Singh)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.